Skip to main content
×
Home
    • Aa
    • Aa

Efficacy of escitalopram compared to citalopram: a meta-analysis

  • Stuart Montgomery (a1), Thomas Hansen (a2) and Siegfried Kasper (a3)
Abstract
Abstract

The aim of this review was to assess the clinical relevance of the relative antidepressant efficacy of escitalopram and citalopram by meta-analysis. Studies in major depressive disorder (MDD) with both escitalopram and citalopram treatment arms were identified. Adult patients had to meet DSM-IV criteria for MDD. The primary outcome measure was the treatment difference in Montgomery–Asberg Depression Rating Scale (MADRS) total score at week 8 (or last assessment if <8 wk). Secondary outcome measures were response (⩾50% improvement from baseline) and remission (MADRS ⩽12). A search of the literature and websites found eight randomized controlled trials (RCTs) and onr naturalistic trial, with a total of 2009 patients (escitalopram, n=995; citalopram, n=1014). Escitalopram was significantly more effective than citalopram in overall treatment effect, with an estimated mean treatment difference of 1.7 points at week 8 (or last assessment if <8 wk) on the MADRS (95% CI 0.8–2.6, p=0.0002) (six RCTs used the MADRS), and in responder rate (8.3 percentage points, 95% CI 4.4–12.3) (eight RCTs) and remitter rate (17.6 percentage points, 95% CI 12.1–23.1) analyses (reported for four RCTs), corresponding to number-needed-to-treat (NNT) values of 11.9 (p<0.0001) for response and 5.7 (p<0.0001) for remission. The overall odds ratios were 1.44 (p<0.0003) for response and 1.86 (p<0.0001) for remission, in favour of escitalopram. In this meta-analysis, the statistically significant superior efficacy of escitalopram compared to citalopram was shown to be clinically relevant.

Copyright
Corresponding author
Address for correspondence: Professor S. Montgomery, PO Box 8751, London W13 8WH, UK. Tel.: +44 20 8997 2689Fax: +44 20 8566 7986Email: Stuart@samontgomery.co.uk
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

IM Anderson (2008). Commentary on ‘Re-evaluation of the efficacy and tolerability of venlafaxine versus SSRI: meta-analysis’ by Weinmann et al. Psychopharmacology 196, 521522.

P Auquier , S Robitail , P-M Llorca , B Rive (2003). Comparison of escitalopram and citalopram efficacy: a meta-analysis. International Journal of Psychiatry in Clinical Practice 7, 259268.

JP Boulenger , AKT Huusom , I Florea , T Baekdal , M Sarchiapone (2006). A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Current Medical Research and Opinion 22, 13311341.

WJ Burke , I Gergel , A Bose (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. Journal of Clinical Psychiatry 63, 331336.

L Colonna , HF Andersen , EH Reines (2005). A randomised, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Current Medical Research and Opinion 21, 16591668.

MA Hamilton (1960). A rating scale for depression. Journal of Neurological and Neurosurgical Psychiatry 23, 5662.

S Kasper , D Baldwin , S Larsson Lönn , JP Boulenger (2009). Superiority of escitalopram to paroxetine in the treatment of depression. European Neuropsychopharmacology 19, 229237.

I Kirsch , BJ Deacon , TB Huedo-Medina , A Scoboria , (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine. Published online: 26 February 2008. doi:10.1371/journal.pubmed.0050045.

SH Kennedy , HF Andersen , ME Thase (2009). Escitalopram in the treatment of major depressive disorder: a meta-analysis. Current Medical Research and Opinion 25, 161175.

I Kirsch , TJ Moore , A Scoboria , SS Nicholls (2002). The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevention & Treatment 5, Article 23.

V Lalit , A Prakash , H Rajendra , M Anukant , et al. (2004). Escitalopram versus citalopram and sertraline: a double-blind controlled, multi-centric trial in Indian patients with unipolar depression. Indian Journal of Psychiatry 46, 333341.

RW Lam , HF Andersen (2006). The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 39, 180184.

C Lançon , C Sapin , I Note , J Farisse (2006). Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: a prospective, naturalistic, 8-week study. International Journal of Psychiatry in Clinical Practice 10, 131137.

U Lepola , A Wade , HF Andersen (2004). Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. International Clinical Psychopharmacology 19, 149155.

UM Lepola , H Loft , EH Reines (2003). Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. International Clinical Psychopharmacology 18, 211217.

P-M Llorca , J-M Azorin , N Despiegel , P Verpillat (2005). Efficacy of escitalopram in patients with severe depression: a pooled analysis. International Journal of Clinical Practice 59, 268275.

J Li , WW Shen , Y Liu , L Xu , et al. (2006). The effectiveness and safety of escitalopram in the treatment of major depression: a randomized double-blind active-drug controlled trial [in Chinese]. Chinese Journal of Evidence-based Medicine [Zhongguo xunzheng yixue zazhi] 6, 552556.

H Melander , T Salmonson , E Abadie , B van Zwieten-Boot (2008). A regulatory apologia – a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. European Neuropsychopharmacology 18, 623627.

SA Montgomery , HF Andersen (2006). Escitalopram versus venlafaxine XR in the treatment of depression. International Clinical Psychopharmacology 21, 297309.

SA Montgomery , M Åsberg (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382389.

SA Montgomery , DS Baldwin , P Blier , NA Fineberg , et al. (2007). Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology 22, 323329.

SA Montgomery , HJ Möller (2009). Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? International Clinical Psychopharmacology 24, 111118.

N Moore , H Verdoux , B Fantino (2005). Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. International Clinical Psychopharmacology 20, 131137.

VY Yevtushenko , AI Belous , YG Yevtushenko , SE Gusinin , et al. (2007). Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clinical Therapeutics 29, 23192332.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The International Journal of Neuropsychopharmacology
  • ISSN: 1461-1457
  • EISSN: 1469-5111
  • URL: /core/journals/the-international-journal-of-neuropsychopharmacology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: